# Pizarra — PT-pseudo_2b3ef1d3a505 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2b3ef1d3a505
Task: 1

Encounter: Urology - outpatient on 23 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 4.2 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.06 ng/mL²
  - PSA velocity: 0.66 ng/mL/yr
  - Prior PSA: 3.7 ng/mL
  - Prostate volume: 69.0 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.81166416 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD
  - Problem list / PMHx: COPD
  - Current medication: tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 4.2 ng/mL. PI-RADS 5. PSAD 0.06. Prostate volume 69 mL. DRE nodus. csPCa 0.81.

Vitals: weight 66 kg, height 185 cm, BMI 19.3, BP 113/72 mmHg, HR 74 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2015).

Chief complaint: Ascending prostate-specific antigen levels and a previous positive biopsy necessitate this clinical review.

History: A 67-year-old mechanical engineer, the patient first registered a prostate-specific antigen level of 2.5 ng/mL during mid-2023. Ongoing surveillance tracked a consistent climb to 4.2 ng/mL, leading to this assessment after an earlier biopsy yielded ISUP Grade Group 1 results. Current complaints include moderate lower urinary tract symptoms, quantified at an IPSS score of 9 out of 35, which remain under conservative management. He resides independently despite being married. A former smoker, he accumulated 30 pack-years before ceasing tobacco use in 2015. His weekly alcohol consumption reaches 31 units, balanced by light weight-training sessions twice each week. Chronic obstructive pulmonary disease requires tiotropium alongside PRN salbutamol. Recent visits covered gastroenterology for a surveillance colonoscopy, pulmonary function testing, and endocrine screening for thyroid status. He reports mild bilateral hearing loss and requests written consultation summaries. Stable right knee osteoarthritis, stemming from a workplace injury decades ago, also requires management.

Physical examination: DRE — texture: firm and irregular; mobility: fixed; asymmetry: pronounced in the right mid-gland region, consistent with a distinct Nodus. General assessment shows stable vital parameters (blood pressure 113/72 mmHg, heart rate 74 bpm) and clear bilateral lung fields. Peripheral lymphadenopathy and hepatosplenomegaly are absent.

Patient info: mechanical engineer; Married; Lives alone.
Next of kin: Nephew.

Lifestyle: alcohol 31 units / week (heavy); exercise Light weight-training at home, 2x/week; IPSS score: 9/35 (moderate LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Pulmonary function test — known COPD follow-up; Endocrine — thyroid screening.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.34 +/- 0.15   (95% CI 0.05-0.64)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.15  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.93 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'supports': p +/- dp does not cross 0.5 but p +/- 1.96*dp does. A direction, not a conclusion; a weighted vote. Measured accuracy in this tier on the labelled cohort: 0.8 over 20 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size and zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend and velocity beyond the headline value?
  - previous_notes (get_previous_notes) -> What is the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trajectory, warrants a re-biopsy decision. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the specific clinical context that the guideline criterion explicitly demands: the status of the prior positive biopsy, the specific PI-RADS 5 score, and the PSA velocity (0.66 ng/mL/yr).
WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY (p=0.34), but the guideline search suggests that a PI-RADS 5 lesion combined with a rising PSA warrants consideration for repeat biopsy, contradicting the prior's low probability. The prior's uncertainty (epistemic dp=0.15) suggests the model is uncertain about the correct path, which is exacerbated by the guideline stating the panel is insufficient.
WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
1. radiology / mpMRI report (get_mri_report) -> To determine if the PI-RADS 5 lesion has changed size or zone compared to a previous study, which is critical for assessing the need for repeat sampling.
2. psa_trend (get_psa_trend) -> To quantify the serial PSA trend and velocity beyond the headline value, which is a key factor in risk stratification mentioned in the guideline search.
3. previous_notes (get_previous_notes) -> To ascertain the prior grade from the previous biopsy and the specific surveillance pathway agreed upon, which is central to the guideline criterion.
4. laboratory_results (get_laboratory_results) -> To review the full lab panel for any other markers that might influence the decision, although the moderator dropped this from the agenda.
GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents, specifically checking if the prior grade is documented, if the lesion changed against a previous MRI, and if a surveillance re-biopsy is due.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Subject: Multiparametric MRI of the Prostate | Institution: Ziekenhuis Gelderse Vallei, Ede | Date: 15 January 2025
The report identifies a PI-RADS 5 lesion in the right mid-peripheral zone, measuring roughly 18 x 15 x 12 mm. It notes no definitive extraprostatic extension or seminal vesicle invasion.

get_psa_trend
The serial PSA trend shows values: Jun 2023: 0.8 ng/mL, Dec 2023: 2.2 ng/mL, Jul 2024: 0.7 ng/mL, Jan 2025: 4.2 ng/mL. The velocity leading up to the current reading is significant.

get_previous_notes
The notes indicate a follow-up test was triggered by a 3.0 ng/mL reading in Dec 2023, and a 4.0 ng/mL assessment threshold was noted. The prior biopsy yielded ISUP Grade Group 1 results.

NOT RETRIEVED
laboratory_results
The full laboratory panel was not retrieved because the moderator's agenda explicitly dropped it, and no immediate question arose from the retrieved documents that would necessitate its retrieval.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion in the right mid-peripheral zone, which is a high-risk finding.
- PSA trend: A significant rise culminating in a current PSA of 4.2 ng/mL, with a velocity indicated by the trend data.
- Previous notes: The prior biopsy result was ISUP Grade Group 1, and the patient is under surveillance following a rising PSA.

AGAINST sampling this patient now:
- Previous notes: The prior biopsy result was ISUP Grade Group 1, which is a lower-risk finding.

WHERE THIS LEANS
The combination of a PI-RADS 5 lesion and a rising PSA trajectory strongly argues for further investigation, despite the lower prior grade.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence, combining the PI-RADS 5 MRI, the significant PSA trend, and the prior ISUP Grade Group 1 biopsy result, strongly leans towards recommending a biopsy, settling the decision for this round.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the specific clinical context that the guideline criterion explicitly demands: the status of the prior positive biopsy, the specific PI-RADS 5 score, and the PSA velocity (0.66 ng/mL/yr).
WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY (p=0.34), but the guideline search suggests that a PI-RADS 5 lesion combined with a rising PSA warrants consideration for repeat biopsy, contradicting the prior's low probability. The prior's uncertainty (epistemic dp=0.15) suggests the model is uncertain about the correct path, which is exacerbated by the guideline stating the panel is insufficient.
WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
1. radiology / mpMRI report (get_mri_report) -> To determine if the PI-RADS 5 lesion has changed size or zone compared to a previous study, which is critical for assessing the need for repeat sampling.
2. psa_trend (get_psa_trend) -> To quantify the serial PSA trend and velocity beyond the headline value, which is a key factor in risk stratification mentioned in the guideline search.
3. previous_notes (get_previous_notes) -> To ascertain the prior grade from the previous biopsy and the specific surveillance pathway agreed upon, which is central to the guideline criterion.
4. laboratory_results (get_laboratory_results) -> To review the full lab panel for any other markers that might influence the decision, although the moderator dropped this from the agenda.
GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents, specifically checking if the prior grade is documented, if the lesion changed against a previous MRI, and if a surveillance re-biopsy is due.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Subject: Multiparametric MRI of the Prostate | Institution: Ziekenhuis Gelderse Vallei, Ede | Date: 15 January 2025
The report identifies a PI-RADS 5 lesion in the right mid-peripheral zone, measuring roughly 18 x 15 x 12 mm. It notes no definitive extraprostatic extension or seminal vesicle invasion.

get_psa_trend
The serial PSA trend shows values: Jun 2023: 0.8 ng/mL, Dec 2023: 2.2 ng/mL, Jul 2024: 0.7 ng/mL, Jan 2025: 4.2 ng/mL. The velocity leading up to the current reading is significant.

get_previous_notes
The notes indicate a follow-up test was triggered by a 3.0 ng/mL reading in Dec 2023, and a 4.0 ng/mL assessment threshold was noted. The prior biopsy yielded ISUP Grade Group 1 results.

NOT RETRIEVED
laboratory_results
The full laboratory panel was not retrieved because the moderator's agenda explicitly dropped it, and no immediate question arose from the retrieved documents that would necessitate its retrieval.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion in the right mid-peripheral zone, which is a high-risk finding.
- PSA trend: A significant rise culminating in a current PSA of 4.2 ng/mL, with a velocity indicated by the trend data.
- Previous notes: The prior biopsy result was ISUP Grade Group 1, and the patient is under surveillance following a rising PSA.

AGAINST sampling this patient now:
- Previous notes: The prior biopsy result was ISUP Grade Group 1, which is a lower-risk finding.

WHERE THIS LEANS
The combination of a PI-RADS 5 lesion and a rising PSA trajectory strongly argues for further investigation, despite the lower prior grade.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence strongly leans towards recommending a biopsy due to the combination of a PI-RADS 5 lesion and a significant PSA trend, despite the prior Grade Group 1 biopsy result. The disagreement remains about the final interpretation of this evidence.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

The statistical prior suggested no biopsy, but the retrieved evidence strongly leans toward biopsy due to the combination of a PI-RADS 5 lesion and a significant PSA trend. This decision overturns the prior by citing the PI-RADS 5 finding from the MRI report and the significant PSA trend data, which together argue for further investigation despite the prior ISUP Grade Group 1 result.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
